Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 24 May 2017 Status changed from suspended to recruiting.
- 20 Oct 2015 Status changed from active, no longer recruiting to suspended, according to ClinicalTrials.gov record.
- 13 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.